GlassScriptPhysician profile
Anna Donaldson
NPI 1790323525
$1,521.92
in general payments reported to CMS, 2019-2025
14 companies · $796 in 2025
The $796 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.67 · 2022: $164 · 2023: $79.67 · 2024: $439 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.16 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.99 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.33 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $143.95 | 2023-2025 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $131.37 | 2025 | Cobenfy |
| Exact Sciences Corporation | $117.07 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $104.69 | 2025 | Rexulti |
| Novo Nordisk INC | $104.16 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $76.91 | 2022-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $47.76 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $27.95 | 2022 | |
| Merck Sharp & Dohme LLC | $19.85 | 2025 | Lagevrio |
| Lundbeck LLC | $16.49 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Donaldson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.